Clinical Trials

We are currently recruiting patients for the the following clinical trials:

  • Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy vs High-Dose Interferon α-2b for Resected High-Risk Melanoma
  • Randomized phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Metastatic Malignant Melanoma
  • Phase II Trial of the MTOR Inhibitor Everolimus in Relapsed or Refractory Cutaneous T-Cell Lymphoma
  • Randomized Open-Label Phase III Trial of Brentuximab Vedotin (SGN-35) vs MD’s Choice (Methotrexate or Bexarotene) in Patients with CD30+ Cutaneous T-Cell Lymphoma